Activation of the alternative pathway of complement during the acute phase of typical haemolytic uraemic syndrome

Clinical and Experimental Immunology

Volumn 181, Issue 1, 2015, Pages 118-125

  Ferraris, J R ^a,b   Ferraris, V ^a   Acquier, A B ^b,c   Sorroche, P B ^a   Saez, M S ^a   Ginaca, A ^d   Mendez, C F ^b,c  

^a HOSPITAL ITALIANO DE BUENOS AIRES   (Argentina)

^b UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^c Facultad de Ciencias Naturales e Instituto M Lillo   (Argentina)

^d HOSPITAL DE NIÑOS RICARDO GUTIÉRREZ   (Argentina)

Author keywords

Acute renal injury; Alternative pathway; Complement; HUS

Indexed keywords

COMPLEMENT; SHIGA TOXIN; ALTERNATIVE COMPLEMENT PATHWAY C3 C5 CONVERTASE; COMPLEMENT C4D; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C3C; COMPLEMENT COMPONENT C4; COMPLEMENT COMPONENT C4B; COMPLEMENT MEMBRANE ATTACK COMPLEX; PEPTIDE FRAGMENT; SC5B-9 PROTEIN COMPLEX;

ACUTE KIDNEY FAILURE; ADOLESCENT; ADULT; ARTICLE; CHILD; COMPLEMENT ACTIVATION; END STAGE RENAL DISEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEMOLYTIC UREMIC SYNDROME; HOSPITALIZATION; HUMAN; KIDNEY INJURY; MAJOR CLINICAL STUDY; MALE; NEUROLOGIC DISEASE; OLIGURIA; PERITONEAL DIALYSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; THROMBOCYTOPENIA; YOUNG ADULT; BLOOD; IMMUNOLOGY; KIDNEY; MIDDLE AGED; PATHOLOGY;

ADOLESCENT; ADULT; CHILD; COMPLEMENT ACTIVATION; COMPLEMENT C3; COMPLEMENT C3-C5 CONVERTASES, ALTERNATIVE PATHWAY; COMPLEMENT C3C; COMPLEMENT C4; COMPLEMENT C4B; COMPLEMENT MEMBRANE ATTACK COMPLEX; FEMALE; HEMOLYTIC-UREMIC SYNDROME; HUMANS; KIDNEY; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PROSPECTIVE STUDIES; SHIGA TOXIN; YOUNG ADULT;

EID: 84930415185     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.12601     Document Type: Article

References (33)

1. Spizzirri FD, Rahman RC, Bibiloni N, Ruscasso JD, Amoreo OR. Childhood hemolytic uremic syndrome in Argentina: long-term follow-up and prognostic features. Pediatr Nephrol 1997; 11:156-60.
2. Rivas M, Miliwebsky E, Chinen I, Deza N, Leotta GA. The epidemiology of hemolytic uremic syndrome in Argentina. Diagnosis of the etiologic agent, reservoirs and routes of transmission. Medicina (B Aires) 2006; 66 (Suppl. 3):27-32.
3. Belardo M. Historical stages of hemolytic uremic syndrome in Argentina (1964-2009). Arch Argent Pediatr 2012; 110:416-20.
4. Garg AX, Suri RS, Barrowman N et al. Long-term renal prognosis of diarrhea-associated hemolytic uremic syndrome: a systematic review, meta-analysis, and meta-regression. JAMA 2003; 290:1360-70.
5. Besbas N, Karpman D, Landau D et al. A classification of hemolytic uremic syndrome and thrombotic thrombocytopenic purpura and related disorders. Kidney Int 2006; 70:423-31.
6. Caprioli J, Noris M, Brioschi S et al. Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood 2006; 108:1267-79.
7. Warwicker P, Goodship TH, Donne RL et al. Genetic studies into inherited and sporadic hemolytic uremic syndrome. Kidney Int 1998; 53:836-44.
8. Noris M, Mescia F, Remuzzi G. STEC-HUS, atypical HUS and TTP are all diseases of complement activation. Nat Rev Nephrol 2012; 8:622-33.
9. Dunkelberger JR, Song WC. Complement and its role in innate and adaptive immune responses. Cell Res 2010; 20:34-50.
10. Gianantonio CA, Vitacco M, Mendilaharzu F, Gallo G. The hemolytic-uremic syndrome. Renal status of 76 patients at long-term follow-up. J Pediatr 1968; 72:757-65.
11. Cameron JS, Vick R. Plasma-C3 in haemolytic uraemic syndrome and thrombotic thrombocytopenic purpura. Lancet 1973; 2:975.
12. Kaplan BS, Thomson PD, MacNab GM. Serum-complement levels in haemolytic uraemic syndrome. Lancet 1973; 2:1505-6.
13. Kim Y, Miller K, Michael AF. Breakdown of C3 and factor B in hemolytic-uremic syndrome. J Lab Clin Med 1977; 89:845-50.
14. Monnens L, Molenaar J, Lambert PH, Proesmans W, van Munster P. The complement system in hemolytic-uremic syndrome. Clin Nephrol 1980; 4:168-71.
15. Robson WL, Leung AK, Fick GH, McKenna AI. Hypocomplementemia and leukocytosis in diarrhea-associated hemolytic uremic syndrome. Nephron 1992; 3:296-99.
16. Thurman JM, Marians R, Emlen W et al. Alternative pathway of complement in children with diarrhea-associated hemolytic uremic syndrome. Clin J Am Soc Nephrol 2009; 4:1920-4.
17. Morigi M, Galbusera M, Gastoldi S et al. Alternative pathway activation of complement by Shiga toxin promotes exuberant C3a formation that triggers microvascular thrombosis. J Immunol 2011; 187:172-80.
18. Ståhl AL, Sartz L, Karpman D. Complement activation on platelet-leukocyte complexes and microparticles in enterohemorrhagic Escherichia coli-induced hemolytic uremic syndrome. Blood 2011; 117:5503-13.
19. Orth D, Khan AB, Naim A et al. Shiga toxin activates complement and binds factor H: evidence for an active role of complement in hemolytic uremic syndrome. J Immunol 2009; 182:6394-400.
20. Lapeyraque AL, Malina M, Fremeaux-Bacchi V et al. Eculizumab in severe Shiga-toxin-associated HUS. N Engl J Med 2011; 364:2561-3.
21. Koch FJ, Jenis EH, Valeski JE. Test for C3 nephritic factor activity by immunofixation electrophoresis. Am J Clin Pathol 1981; 76:63-67.
22. Moshage H. Cytokines and the hepatic acute phase response. J Pathol 1997; 181:257-66.
23. Muscari A, Bozzoli C, Puddu G et al. Association of serum C3 levels with the risk of myocardial infarction. Am J Med 1995; 98:357-64.
24. Engstrom G, Hedblad B, Berglund G, Janzon L, Lindgarde F. Plasma levels of complement C3 is associated with development of hypertension: a longitudinal cohort study. J Hum Hypertens 2007; 21: 276-82.
25. Ståhl AL, Svensson M, Mörgelin M et al. Lipopolysaccharide from enterohemorrhagic Escherichia coli binds to platelets through TLR4 and CD62 and is detected on circulating platelets in patients with hemolytic uremic syndrome. Blood 2006; 108:167-76.
26. Del Conde I, Crúz MA, Zhang H, López JA, Afshar-Kharghan V. Platelet activation leads to activation and propagation of the complement system. J Exp Med 2005; 201:871-9.
27. Ferraris V, Acquier A, Ferraris JR, Vallejo G, Paz C, Mendez CF. Oxidative stress status during the acute phase of haemolytic uraemic syndrome. Nephrol Dial Transplant 2011; 26:858-64.
28. Collard CD, Lekowski R, Jordan JE, Agah A, Stahl GL. Complement activation following oxidative stress. Mol Immunol 1999; 36:941-8.
29. Collard CD, Väkevä A, Morrissey MA et al. Complement activation after oxidative stress: role of the lectin complement pathway. Am J Pathol 2000; 156:1549-56.
30. Collard CD, Montalto MC, Reenstra WR, Buras JA, Stahl GL. Endothelial oxidative stress activates the lectin complement pathway: role of cytokeratin 1. Am J Pathol 2001; 159:1045-54.
31. Hart ML, Walsh MC, Stahl GL. Initiation of complement activation following oxidative stress. In vitro and in vivo observations. Mol Immunol 2004; 41:165-71.
32. Wu Z, Lauer TW, Sick A, Hackett SF, Campochiaro PA. Oxidative stress modulates complement factor H expression in retinal pigmented epithelial cells by acetylation of FOXO3. J Biol Chem 2007; 282:22414-25.
33. Amer J, Zelig O, Fibach E. Oxidative status of red blood cells, neutrophils, and platelets in paroxysmal nocturnal hemoglobinuria. Exp Hematol 2008; 36: 369-377.